Molecular-based method of cancer diagnosis and prognosis

US9181589B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Steven K. Libutti · North Potomac, US
• Mei He · Hangzhou City, CN

Key dates

• Filing date: Mar 17, 2014
• Grant date: Nov 10, 2015
• Expiry date: Mar 17, 2034

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/56
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

A gene profiling signature for diagnosis and prognosis of cancer patients is disclosed herein. In one embodiment, the gene signature includes 32 or 79 cancer survival factor-associated genes. Thus, provided herein is a method of determining the prognosis of a subject with a tumor by detecting expression of five of more cancer survival factor-associated genes in a tumor sample and comparing expression of the five or more cancer survival factor-associated genes in the tumor sample to a control. In some examples, an increase in expression of ABCF1, CORO1C, DPP3, PREB, UBE3A, and PTDSS1 in a tumor sample compared to a control sample indicates poor prognosis. Further provided are arrays including probes or antibodies specific for a plurality of cancer survival factor-associated genes or proteins.